Patents by Inventor Tamao Endo

Tamao Endo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11040087
    Abstract: Provided is a therapeutic agent that effectively acts on a disease associated with abnormal glycosylation of dystroglycan. Also provided is a testing method for diseases associated with abnormal glycosylation of dystroglycan. Specifically, provided is a therapeutic agent for diseases associated with abnormal glycosylation of dystroglycan, containing CDP-ribitol as an active ingredient. Ribitol-phosphate is important in the glycan structure of dystroglycan. In order for ribitol-phosphate to be incorporated into a dystroglycan glycan, a material therefor (sugar donor) is required. In the present invention, it has been found for the first time that CDP-ribitol serves as the sugar donor. It has been confirmed that the glycan of ISPD-deficient cells can be restored by administering CDP-ribitol. Thus, the present invention, which allows CDP-ribitol to be utilized for supplementation therapy, has been completed.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: June 22, 2021
    Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY, OSAKA PREFECTURAL HOSPITAL ORGANIZATION
    Inventors: Tatsushi Toda, Kazuhiro Kobayashi, Motoi Kanagawa, Tamao Endo, Hiroshi Manya, Yoshinao Wada, Michiko Tajiri
  • Publication number: 20200188491
    Abstract: Provided is a therapeutic agent that effectively acts on a disease associated with abnormal glycosylation of dystroglycan. Also provided is a testing method for diseases associated with abnormal glycosylation of dystroglycan. Specifically, provided is a therapeutic agent for diseases associated with abnormal glycosylation of dystroglycan, containing CDP-ribitol as an active ingredient. Ribitol-phosphate is important in the glycan structure of dystroglycan. In order for ribitol-phosphate to be incorporated into a dystroglycan glycan, a material therefor (sugar donor) is required. In the present invention, it has been found for the first time that CDP-ribitol serves as the sugar donor. It has been confirmed that the glycan of ISPD-deficient cells can be restored by administering CDP-ribitol. Thus, the present invention, which allows CDP-ribitol to be utilized for supplementation therapy, has been completed.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 18, 2020
    Inventors: Tatsushi TODA, Kazuhiro KOBAYASHI, Motoi KANAGAWA, Tamao ENDO, Hiroshi MANYA, Yoshinao WADA, Michiko TAJIRI
  • Patent number: 8609346
    Abstract: It is an object of the present invention to detect a change in the metabolism of a glycoprotein having an ?2,6-sialyl residue, which is contained in blood, so as to provide an agent and a method for diagnosing sporadic Alzheimer's disease. The present invention provides an agent for diagnosing Alzheimer's disease, which comprises lectin used for detecting an ?2,6-sialyl residue-containing glycoprotein.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: December 17, 2013
    Assignee: Riken
    Inventors: Shinobu Kitazume, Ritsuko Oka, Yasuhiro Hashimoto, Tamao Endo, Makoto Higuchi, Hiroyuki Arai, Takaomi Saido, Keiko Sato
  • Publication number: 20110076704
    Abstract: It is an object of the present invention to detect a change in the metabolism of a glycoprotein having an ?2,6-sialyl residue, which is contained in blood, so as to provide an agent and a method for diagnosing sporadic Alzheimer's disease. The present invention provides an agent for diagnosing Alzheimer's disease, which comprises lectin used for detecting an ?2,6-sialyl residue-containing glycoprotein.
    Type: Application
    Filed: May 11, 2006
    Publication date: March 31, 2011
    Applicant: RIKEN
    Inventors: Shinobu Kitazume, Ritsuko Oka, Yasuhiro Hashimoto, Yuji Sato, Tamao Endo, Makoto Higuchi, Hiroyuki Arai, Takaomi Saido, Keiko Sato
  • Patent number: 7217548
    Abstract: The present invention relates to an enzyme having novel N-acetylglucosaminyltransferase (OMGnT) activity, a polynucleotide encoding the enzyme, a recombinant polynucleotide comprising the polynucleotide, a host cell comprising the recombinant polynucleotide, a method for producing an enzyme protein having OMGnT activity by culturing the host cell in a medium, and a method for modifying a sugar chain structure with the enzyme and a carbohydrate having a sugar chain structure modified by the method. This enzyme enables the production of complex carbohydrates, which could not be formed with conventional glycosyltransferases.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: May 15, 2007
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Aruto Yoshida, Yoriko Takeuchi, legal representative, Tamao Endo, Hiroshi Manya, Yasunori Chiba, Yoshifumi Jigami, Shigemi Sugioka, Makoto Takeuchi, deceased
  • Publication number: 20040132130
    Abstract: The present invention relates to an enzyme having novel N-acetylglucosaminyltransferase (OMGnT) activity, a polynucleotide encoding the enzyme, a recombinant polynucleotide comprising the polynucleotide, a host cell comprising the recombinant polynucleotide, a method for producing an enzyme protein having OMGnT activity by culturing the host cell in a medium, and a method for modifying a sugar chain structure with the enzyme and a carbohydrate having a sugar chain structure modified by the method. This enzyme enables the production of complex carbohydrates, which could not be formed with conventional glycosyltransferases.
    Type: Application
    Filed: September 15, 2003
    Publication date: July 8, 2004
    Inventors: Aruto Yoshida, Makoto Takeuchi, Yoriko Takeuchi, Tamao Endo, Hirosi Manya, Yasunori Chiba, Yoshifumi Jigami, Shigemi Sugioka